HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

HCMV infection in renal transplant recipients: a retrospective cohort study.

Abstract
Human Cytomegalovirus (HCMV) represents the most common viral complication affecting solid organ transplant recipients (SOTRs) and its management is still debated. This study analyzes the association between HCMV infection and renal transplant recipients' outcomes. From January 2008 through December 2009, 97 consecutive renal transplant recipients were retrospectively studied. HCMV disease prevention was pursued by pre-emptive therapy, reserving long-term prophylaxis for high-risk patients. A total of 32/97 patients (32.9%) developed HCMV positivity in blood for a cumulative estimated proportion at 3 months post-transplantation of 0.21. HCMV disease developed in 7 patients (7.2%), while 25 patients had asymptomatic infection (25.7%). No patient died from HCMV. HCMV disease, older graft age and post-transplant renal dysfunction were independent predictors of rejection while HCMV infection without disease was associated with a higher number of other complications. The use of basiliximab was independently associated with a reduced hazard of HCMV infection/ disease. In renal transplant recipients HCMV infection still represents a major issue influencing the outcome, not only because of the potential to develop the disease and its link to graft rejection, but also in terms of higher number of complications. The choice of different immunosuppressive strategies might be associated with HCMV replication.
AuthorsCamilla Puttini, Mario Carmellini, Guido Garosi, Barbara Rossetti, Maria Letizia Riccio, Giacinta Tordini, Maria Grazia Cusi, Andrea De Luca, Giacomo Zanelli
JournalThe new microbiologica (New Microbiol) Vol. 36 Issue 4 Pg. 363-71 (Oct 2013) ISSN: 1121-7138 [Print] Italy
PMID24177298 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antiviral Agents
  • Recombinant Fusion Proteins
  • Basiliximab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antiviral Agents (therapeutic use)
  • Basiliximab
  • Cytomegalovirus (isolation & purification, physiology)
  • Cytomegalovirus Infections (etiology, prevention & control, virology)
  • Female
  • Humans
  • Kidney Transplantation (adverse effects)
  • Male
  • Middle Aged
  • Postoperative Complications (etiology, prevention & control, virology)
  • Recombinant Fusion Proteins (therapeutic use)
  • Retrospective Studies
  • Transplants (virology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: